The US Food and Drug Administration approval of Bristol Myers Squibb Company’s chimeric antigen receptor T-cell (CAR-T) therapy Breyanzi (lisocabtagene maraleucel; liso-cel) has been a long time coming, but that has given the company time to prepare for launch against two established competitors.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Third Cell Therapy For Lymphoma Approved In The US
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
